Amundi Trims Stake in Repligen Corporation $RGEN

Key Points

• Amundi cut its Repligen stake by 73% in the second quarter, selling 32,842 shares and retaining 12,117 shares valued at approximately $1.65 million. Institutional investors collectively own 97.64% of the company.
• Repligen reported quarterly EPS of $0.54, exceeding estimates of $0.45, while revenue rose 11.9% year over year to $204.13 million. The company issued fiscal 2026 EPS guidance of $2.03–$2.09.
• Analyst sentiment remains favorable, with the stock carrying a consensus “Buy” rating and a $168.57 average price target. Shares recently opened at $165.18, compared with a 52-week range of $100.99 to $188.73.

Amundi lowered its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 73.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,117 shares of the biotechnology company's stock after selling 32,842 shares during the period. Amundi's holdings in Repligen were worth $1,653,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. ABS Investment Management LLC purchased a new position in Repligen during the 2nd quarter valued at about $191,016,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen in the 3rd quarter valued at approximately $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the fourth quarter valued at about $36,000. Itau Unibanco Holding S.A. lifted its stake in Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 104 shares during the period. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Repligen during the second quarter worth about $52,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Performance

NASDAQ:RGEN opened at $165.18 on Monday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $188.73. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.32 billion, a price-to-earnings ratio of 226.27, a price-to-earnings-growth ratio of 3.01 and a beta of 1.05. The company has a fifty day simple moving average of $158.22 and a two-hundred day simple moving average of $135.29.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm had revenue of $204.13 million during the quarter, compared to analysts' expectations of $201.59 million. During the same period in the prior year, the firm earned $0.26 EPS. The business's revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RGEN. Benchmark raised Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Zacks Research upgraded Repligen from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 13th. Evercore reaffirmed an "outperform" rating and set a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Finally, Citigroup upgraded shares of Repligen to a "buy" rating in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Repligen currently has an average rating of "Buy" and a consensus target price of $168.57.

Insider Transactions at Repligen

In other news, CFO Jason Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company's stock.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.